Base Genomics is an epigenetics company focusing on developing a blood test for early-stage cancer and minimal residual disease.
Base Genomics has raised €9.8M across 1 funding round from 1 investor, most recently a Seed round in Mar 2020. Based in Oxford, UK; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-03-06 | Seed | €9.8M |
| Oxford Sciences Innovation |
| View deal → |
